Transforming ovarian cancer care by targeting minimal residual disease.

Humans Female Neoplasm, Residual Ovarian Neoplasms / drug therapy Carcinoma, Ovarian Epithelial / therapy

Journal

Med (New York, N.Y.)
ISSN: 2666-6340
Titre abrégé: Med
Pays: United States
ID NLM: 101769215

Informations de publication

Date de publication:
10 11 2023
Historique:
received: 10 07 2023
revised: 09 08 2023
accepted: 22 08 2023
medline: 13 11 2023
pubmed: 12 11 2023
entrez: 11 11 2023
Statut: ppublish

Résumé

Frontline treatment and resultant cure rates in patients with advanced ovarian cancer have changed little over the past several decades. Here, we outline a multidisciplinary approach aimed at gaining novel therapeutic insights by focusing on the poorly understood minimal residual disease phase of ovarian cancer that leads to eventual incurable recurrences.

Identifiants

DOI: 10.1016/j.medj.2023.08.004 PMID: 37951209
pubmed: 37951209
pii: S2666-6340(23)00260-X
doi: 10.1016/j.medj.2023.08.004
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

755-760

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests A.A.J., R.G., D.Z., R.T.H., B.C.L., S.L., S.N.W., E.M., M.J.W., S.G., C.A., and K.L. are clinical investigators whose institutions have received clinical trial support from Imunon. This team effort on minimal residual disease in ovarian cancer is supported by funding from Break Through Cancer. N.M.B. and T.P. receive support from Break Through Cancer through their Break Through Cancer Scientist Program.

Auteurs

Amir A Jazaeri (AA)

University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: aajazaeri@mdanderson.org.

Rachel Grisham (R)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Anne Knisely (A)

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Stefani Spranger (S)

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

Dmitriy Zamarin (D)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

R Tyler Hillman (RT)

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Barrett C Lawson (BC)

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Kathleen H Burns (KH)

Dana-Farber Cancer Institute, Boston, MA, USA.

Sanghoon Lee (S)

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Shannon N Westin (SN)

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Enrico Moiso (E)

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

Marc J Williams (MJ)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Neelkanth M Bardhan (NM)

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Break Through Cancer, Cambridge, MA, USA.

Thomas Pisanic (T)

Break Through Cancer, Cambridge, MA, USA.

Ursula Matulonis (U)

Dana-Farber Cancer Institute, Boston, MA, USA.

Britta Weigelt (B)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

IeMing Shih (I)

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.

Panagiotis A Konstantinopoulos (PA)

Dana-Farber Cancer Institute, Boston, MA, USA.

Stephanie Gaillard (S)

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.

Linghua Wang (L)

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Carol Aghajanian (C)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Alan D D'Andrea (AD)

Dana-Farber Cancer Institute, Boston, MA, USA.

Paula Hammond (P)

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

Sohrab Shah (S)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Kai W Wucherpfennig (KW)

Dana-Farber Cancer Institute, Boston, MA, USA.

Karen H Lu (KH)

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Transforming ovarian cancer care by targeting...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Maladie résiduelle › Transforming ovarian cancer care by targeting...
questionsmedicales.fr › Maladies endocriniennes › Troubles gonadiques › Maladies ovariennes › Tumeurs de l'ovaire › Transforming ovarian cancer care by targeting...
questionsmedicales.fr › Maladies endocriniennes › Troubles gonadiques › Maladies ovariennes › Tumeurs de l'ovaire › Carcinome épithélial de l'ovaire › Transforming ovarian cancer care by targeting...